Clinuvel Pharmaceuticals (CUVL) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Clinuvel Pharmaceuticals (CUVL) is Strong Underperform.

The composite score behind that read is -0.60, weighing +0.10 of bullish evidence against -0.66 bearish.

Clinuvel Pharmaceuticals last closed at $5.02, +1.21% on the session.

Against the IVW growth benchmark the position is +0.27% over the forecast window.

The read is built from 12 underlying insights — 2 bullish and 10 bearish.

Agreement across those insights is 83%.

32 graded predictions for CUVL so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

Clinuvel Pharmaceuticals is classified under Health Care / Biotechnology, with a market capitalisation of $250.42M.

StockMap tracks Clinuvel Pharmaceuticals as the 221st largest of the 390 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 200 Moderate Underperform, 127 Neutral, 56 Strong Underperform and 7 Moderate Outperform.

On that composite Clinuvel Pharmaceuticals ranks 366th of 390 in the group, against a group median of -0.27.